We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0K16 market cap is 0. The company's latest EPS is USD -1.0793 and P/E is -10.68.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 34.93M | 58.55M | 99.67M | 148.62M | 202.09M |
| Operating Income | -98.95M | -153.07M | -69.91M | -65.33M | -49.23M |
| Net Income | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 240.44M | 209.07M | 257.48M | 177.98M | 189M |
| Total Liabilities | 160.99M | 282.03M | 175.61M | 159.48M | 209.69M |
| Total Equity | 79.46M | -72.96M | 81.88M | 18.5M | -20.69M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -93.38M | -57.87M | -33.39M | -84.91M | -34.01M |
| Investing | -23.43M | 12.19M | 4.03M | -2.94M | -1.63M |
| Financing | 133.55M | 38.35M | 73.05M | -4.15M | 44.64M |
| Market Cap | 0 |
| Price to Earnings Ratio | -10.68 |
| Price to Sales Ratio | 3.26 |
| Price to Cash Ratio | 10.49 |
| Price to Book Ratio | -31.85 |
| Dividend Yield | - |
| Shares Outstanding | 57.15M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Evolus Inc |
| Address |
838 walker road dover, delaware 19904 |
| Website | https://www.evolus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
